Meeting
2020 Genitourinary Cancers Symposium
PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase III trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC).
Authors
Mary-Ellen Taplin
Dana-Farber Cancer Institute, Boston, MA
Mary-Ellen Taplin , Martin Gleave , Christopher P. Evans , Eleni Efstathiou , Philip W. Kantoff , Ashley Ross , Neal D. Shore , Alberto Briganti , Boris A. Hadaschik , Axel Heidenreich , Oliver Brendan Rooney , Shaozhou Ken Tian , Lisa Wetherhold , Weichun Xu , Shinta Cheng , Sabine Doris Brookman-May , Angela Lopez-Gitlitz , Adam S. Kibel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03767244
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr TPS383)
Abstract #
TPS383
Poster Bd #
Q3
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients (pts) with localized or locally advanced high-risk prostate cancer (PC).
First Author: Adam S. Kibel
Poster
2023 ASCO Annual Meeting
Digital histopathology-based multimodal artificial intelligence scores predict risk of progression in a randomized phase III trial in patients with nonmetastatic castration-resistant prostate cancer.
First Author: Felix Y Feng
Poster
2023 ASCO Genitourinary Cancers Symposium
Cardiovascular and thromboembolic events associated with intense neoadjuvant androgen deprivation therapy followed by prostatectomy in patients with localized prostate cancer: A meta-analysis of clinical trials.
First Author: Eduardo Felicio Campos
Poster
2022 ASCO Annual Meeting
A phase III double blinded study of early intervention after radical prostatectomy with androgen deprivation therapy with darolutamide versus placebo in men at highest risk of prostate cancer metastasis by genomic stratification (ERADICATE).
First Author: Alicia K. Morgans